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Introduction
Despite being the most evolutionarily conserved among the 
caspases, the role of caspase-2 in apoptosis remains unclear. 
However, the need to understand the mechanisms of regulation 
of this caspase has been underscored by growing evidence that 
caspase-2 can function as a tumor suppressor (Puccini et al., 
2013a). Loss of caspase-2 has been associated with accelera-
tion of tumorigenesis in murine models of Eµ-Myc lymphoma, 
ATM-deficient lymphoma, MMTV/c-neu mammary tumors, 
and K-ras–induced lung tumors (Ho et al., 2009; Pan et al., 
2009; Parsons et al., 2013; Puccini et al., 2013b; Terry et al., 
2015). Such phenotypes are often accompanied by increases in 
genomic instability and aneuploidy (Dorstyn et al., 2012; Par-
sons et al., 2013; Puccini et al., 2013b). This strongly suggests 
that caspase-2 is activated in response to DNA-damaging in-
sults to remove damaged cells. Caspase-2 has been shown to 
be activated by DNA damage in both p53-dependent (Lassus et 
al., 2002; Robertson et al., 2002) and p53-independent manners 
(Sidi et al., 2008; Myers et al., 2009; Pan et al., 2009; Ando et 
al., 2012). However, the upstream regulators of caspase-2 in this 
context remain poorly defined.
Caspase-2 is activated by proximity-induced dimerization 
of inactive monomers after recruitment to specific high molecu-
lar weight protein complexes, which can be considered “activa-
tion platforms” (Muzio et al., 1998; Salvesen and Dixit, 1999; 
Boatright et al., 2003; Baliga et al., 2004). Although there is 
some evidence that caspase-2 can be recruited to the TNF re-
ceptor death-inducing signaling complex (Ahmad et al., 1997; 
Duan and Dixit, 1997), the most well-defined activation plat-
form for caspase-2 is the PIDDosome. This complex includes 
the scaffold protein p53-induced protein with a death domain 
(PIDD), which binds and promotes the oligomerization of the 
adaptor protein RIP-associated ICH-1/CAD-3 homologous pro-
tein with a death domain (RAI DD) via a protein–protein inter-
action motif present in both proteins called death domain (DD; 
Tinel and Tschopp, 2004). RAI DD, in turn, binds caspase-2 
via a related motif called caspase recruitment domain (CARD; 
Duan and Dixit, 1997; Jang and Park, 2013). The PIDDosome 
was first described as spontaneously forming after a tempera-
ture shift of cell extracts (heated to 37°C for 30 min; Tinel and 
Tschopp, 2004) and has a predicted molecular weight of 696.8 
kD (Park et al., 2007).
The PIDDosome (PIDD–RAI DD–caspase-2 complex) is considered to be the primary signaling platform for caspase-2 
activation in response to genotoxic stress. Yet studies of PIDD-deficient mice show that caspase-2 activation can proceed 
in the absence of PIDD. Here we show that DNA damage induces the assembly of at least two distinct activation plat-
forms for caspase-2: a cytoplasmic platform that is RAI DD dependent but PIDD independent, and a nucleolar platform 
that requires both PIDD and RAI DD. Furthermore, the nucleolar phosphoprotein nucleophosmin (NPM1) acts as a scaf-
fold for PIDD and is essential for PIDDosome assembly in the nucleolus after DNA damage. Inhibition of NPM1 impairs 
caspase-2 processing, apoptosis, and caspase-2–dependent inhibition of cell growth, demonstrating that the NPM1- 
dependent nucleolar PIDDosome is a key initiator of the caspase-2 activation cascade. Thus we have identified the 
nucleolus as a novel site for caspase-2 activation and function.
NPM1 directs PIDDosome-dependent caspase-2 
activation in the nucleolus
Kiyohiro Ando,1,2* Melissa J. Parsons,3* Richa B. Shah,1,2 Chloé I. Charendoff,3 Sheré L. Paris,3 Peter H. Liu,1,2 
Sara R. Fassio,3 Brittany A. Rohrman,3 Ruth Thompson,1,2 Andrew Oberst,5 Samuel Sidi,1,2** and 
Lisa Bouchier-Hayes3,4**
1Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY 10029
2Department of Developmental and Regenerative Biology and Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
3Department of Pediatrics, Division of Hematology-Oncology and 4Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030
5Department of Immunology, University of Washington, Seattle, WA 98109
© 2017 Ando et al. This article is distributed under the terms of an Attribution–Noncommercial–
Share Alike–No Mirror Sites license for the first six months after the publication date (see http 
://www .rupress .org /terms /). After six months it is available under a Creative Commons 
License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at 
https ://creativecommons .org /licenses /by -nc -sa /4 .0 /).
*K. Ando and M.J. Parsons contributed equally to this paper.
**S. Sidi and L. Bouchier-Hayes contributed equally to this paper.
Correspondence to Lisa Bouchier-Hayes: lxbouchi@txch.org; or Samuel Sidi: 
samuel.sidi@mssm.edu
Abbreviations used: AML, acute myeloid leukemia; BiFC, bimolecular fluo-
rescence complementation; CARD, caspase recruitment domain; CR, central 
region; DD, death domain; DFC, dense fibrillar center; FC, fibrillar center; 
GC, granular component; IR, irradiation; NLS, nuclear localization sequence; 
sgRNA, single-guide RNA; WT, wild-type.
o
n
 M
ay 30, 2017
D
ow
nloaded from
 
Published April 21, 2017
JCB • 20172
The requirement of PIDD for caspase-2 activation has 
been subject to some controversy (Bouchier-Hayes and Green, 
2012). PIDD can engage caspase-2 in response to genotoxic 
stress, and PIDD overexpression induces growth suppression 
that is entirely dependent on RAI DD and partially dependent 
on caspase-2 (Lin et al., 2000; Berube et al., 2005). However, 
studies of cells from PIDD-deficient mice show that caspase-2 
processing can proceed in the absence of PIDD in response 
to etoposide and γ-irradiation (IR) and that the caspase-2– 
containing high molecular weight complex formed upon tem-
perature shift still assembles in the absence of PIDD (Manzl 
et al., 2009, 2012). One likely explanation for these discrepan-
cies resides in the recent identification of potent inhibitors of 
PIDDosome assembly that act to counter platform formation 
after IR. These negative regulators include the mitotic check-
point factor BubR1, which competes with RAI DD for docking 
onto the PIDD DD, and the DNA-damage checkpoint kinase 
Chk1, which negates ATM-mediated phosphorylation of the 
PIDD DD through an unknown mechanism, thereby decreasing 
the affinity of PIDD for RAI DD (Ando et al., 2012; Thompson 
et al., 2015). Although the significance of Chk1- or BubR1- 
mediated PIDDosome control is not yet completely clear, ge-
netic or pharmacologic reduction of either protein relieves 
PIDD from its endogenous inhibitors, unveiling a bona fide 
PIDDosome pathway that mediates apoptosis after IR (Ando et 
al., 2012; Thompson et al., 2015).
To directly assess the role of PIDD in caspase-2 activation 
in response to DNA damage, we used caspase-2 bimolecular 
fluorescence complementation (BiFC). BiFC uses nonfluores-
cent fragments of the yellow fluorescent protein Venus (“split 
Venus”) that can associate to reform the fluorescent complex 
when fused to interacting proteins (Shyu et al., 2006). When 
the prodomain of caspase-2 is fused to each half of split Venus, 
recruitment of caspase-2 to its activation platform and the sub-
sequent induced proximity results in enforced association of the 
two Venus halves. Thus Venus fluorescence acts as a readout 
for caspase-2–induced proximity, the proximal step in its acti-
vation (Bouchier-Hayes et al., 2009). Using this approach, we 
reveal that in response to DNA damage, caspase-2 activation 
platforms assemble in the cytoplasm as well as, surprisingly, 
the nucleolus. This differential localization of activation plat-
form assembly appears to be determined by PIDD, because 
PIDD is required only for caspase-2–induced proximity in the 
nucleolus. Furthermore, we identify a direct PIDD-interaction 
partner in the nucleolus, the phosphoprotein nucleophosmin 
(NPM1). NPM1 is the most frequently mutated gene in adult 
acute myeloid leukemia (AML) and has been previously impli-
cated in apoptosis albeit through unknown mechanisms (Falini 
et al., 2005; Grisendi et al., 2005). Here, we show that NPM1 is 
directly and specifically responsible for PIDDosome assembly 
in the nucleolus, an event essential for PIDDosome-mediated 
apoptosis after DNA damage.
Results
DNA damage induces caspase-2 activation 
platform assembly in the cytoplasm and 
the nucleolus
To investigate caspase-2 activation platform assembly induced 
by DNA damage, we used the caspase-2 BiFC assay (Bouchier- 
Hayes et al., 2009). We transiently expressed the C2-Pro BiFC 
pair (aa 1–147) in HeLa cells and observed induction of BiFC 
in response to a range of DNA-damaging agents, including the 
topoisomerase II inhibitor etoposide, as we have previously 
reported (Bouchier-Hayes et al., 2009; Fig. 1 A). We also ob-
served an increase in caspase-2 BiFC in response to the pre-
viously untested topoisomerase I inhibitors camptothecin, 
irinotecan, and topotecan. As controls for the assay, we used 
the tubulin disruptors taxol and vincristine, known caspase-2 
activators that induced BiFC as expected. Actinomycin D, a 
proapoptotic stimulus that does not engage caspase-2 (O’Reilly 
et al., 2002; Bouchier-Hayes et al., 2009), had little effect.
To overcome the limitations of transient transfection and 
to validate the results shown in Fig.  1  A, we created stable 
caspase-2 BiFC reporter cell lines. We designed a bicistronic 
construct in which the C2 Pro-VC and C2 Pro-VN are expressed 
in a single vector separated by the viral 2A self-cleaving peptide 
(Fig. 1 B). This ensures that the caspase-2 BiFC components 
are expressed at equal levels as they are translated from a single 
mRNA transcript. The parental HeLa line showed very small 
yet specific responses to the panel of drugs tested, comprising 
camptothecin, irinotecan, topotecan, etoposide, and vincristine 
(Fig. 1 C). To enhance the sensitivity of the stable cell line, we 
made single-cell clones and identified a clone that showed ro-
bust and reproducible responses to each of the agents (Fig. 1 C). 
The cloned line showed negligible background BiFC fluores-
cence, indicating minimal spontaneous Venus reassociation. 
Thus the “cleavage” mediated by the 2A peptide was complete 
and produced two spatially separated C2 Pro-BiFC proteins 
in unstimulated cells. The topoisomerase I inhibitors campto-
thecin, irinotecan, and topotecan each induced high levels of 
caspase-2 BiFC, identifying a novel class of DNA-damaging 
agents that induce caspase-2 activation platform assembly. We 
analyzed the cells under the same conditions by microscopy 
(Figs. 1 C and S1 A) and flow cytometry (Fig. S1 B), and the 
results were nearly identical.
Surprisingly, imaging of the HeLa.C2 Pro-VC-2A-C2 
Pro-VN-2A-mCherry clone (HeLa.C2 Pro-BiFC) revealed that 
caspase-2 BiFC induced in response to DNA-damaging agents 
often manifested as one or more large fluorescent puncta that 
appeared to be located in the nucleolus (Fig. S1 A). In contrast, 
caspase-2 BiFC induced by vincristine was primarily detected 
as a series of small fluorescent complexes localized in the cy-
toplasm (Fig. S1 A). To confirm that caspase-2 BiFC localized 
to the nucleolus in response to topoisomerase I inhibition, we 
expressed fibrillarin-CFP, a nucleolar protein, in the HeLa.C2 
Pro-BiFC cells (Fig. 1 D). A substantial number of cells treated 
with camptothecin, irinotecan, or topotecan induced caspase-2 
BiFC in the nucleolar compartment that was delineated by 
concentrated fibrillarin-CFP fluorescence. Thus a large pro-
portion of cells treated with topoisomerase I inhibitors showed 
caspase-2 activation localized to the nucleolus, whereas other 
cells induced caspase-2 BiFC that localized to either the cy-
toplasm or nucleus (Fig. 1 E). In comparison, in cells exposed 
to etoposide, only a small fraction of the cells induced nucle-
olar-localized caspase-2 BiFC, whereas vincristine induced 
caspase-2 BiFC only in the cytoplasm or nucleus (Fig.  1  E). 
Similar results were observed in U2OS cells stably expressing 
the C2 Pro-BiFC components (Fig. S1, C and D). Cells treated 
with IR plus Chk1 inhibitor (Chk1i, Gö6976), a genotoxic stim-
ulus known to trigger endogenous PIDDosome assembly (Ando 
et al., 2012), also engaged caspase-2 BiFC in both nucleolar and 
cytoplasmic compartments (Fig. 1, F and G). Lower doses of 
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Figure 1. DNA-damaging agents induce caspase-2 BiFC in the nucleolus. (A) HeLa cells transfected with C2-Pro VC (20 ng), C2-Pro VN (20 ng), and 
dsRed-mito as a transfection reporter (10 ng) were treated with camptothecin (100 µM), irinotecan (100 µM), topotecan (100 µM), etoposide (100 µM), 
actinomycin D (1 µM), taxol (10 µg/ml), or vincristine (10 µM) plus qVD-OPH (20 µM) to prevent cell detachment caused by apoptosis. Cells were assessed 
for the percentage of dsRed-positive transfected cells that were Venus+ at 24 h, determined from at least 30 microscopy images per well. Results are the 
mean of three independent experiments ± SD. *, P < 0.05; **, P < 0.005 compared with untreated sample. (B) Schematic representation of caspase-2 
structure and BiFC constructs. Constructs containing the caspase-2 prodomain (C2 Pro) are shown, each fused to the C- or N-terminal fragment of Venus. 
The bicistronic construct consists of C2 Pro-VC and C2 Pro-VN linked by a 2A self-cleaving peptide. (C) HeLa cells stably expressing C2 Pro-VC-2A-C2 
Pro-VN-2A-mCherry (HeLa.C2 Pro-BiFC; parent) were single-cell cloned (clone), and each was treated with the indicated drugs (100 µM) plus qVD-OPH 
(20 µM). After 24 and 48 h, the percentage of mCherry-positive cells that were Venus+ was determined from at least 30 microscopy images per well. 
Results are the mean of three independent experiments ± SD. *, P < 0.05; **, P < 0.005; ***, P < 0.0005 compared with the untreated sample in each 
group. (D) HeLa.C2 Pro-BiFC cells transfected with fibrillarin-CFP were treated with camptothecin (100 µM), irinotecan (100 µM), topotecan (100 µM), 
etoposide (100 µM), or vincristine (10 µM) plus qVD-OPH (20 µM) for 24 h. Representative images show cells (red) with caspase-2 BiFC (yellow) in the 
nucleolus (blue) or cytoplasm after treatment. Bars, 10 µm. (E) Percentage of cells treated as in D that were Venus+ in the nucleolus, nucleus, or cytoplasm 
was determined from at least 30 microscopy images per well. Results are the mean of three independent experiments ± SD. *, P < 0.05 determined from the 
percentage of nucleolar Venus-positive cells compared with untreated. (F) HeLa.C2 Pro-BiFC cells were treated with or without the Chk1 inhibitor, Gö6976 
(0.5 µM, 1 µM), ± IR (10 Gy) plus qVD-OPH (20 µM). The percentage of cells that were Venus+ in the nucleolus, nucleus, or cytoplasm was determined at 
24 h from at least 50 microscopy images per well. Results are the mean of three independent experiments ± SD. *, P < 0.05 determined from the percent-
age of nucleolar Venus-positive cells compared with untreated. (G) Representative confocal images show caspase-2 BiFC (yellow) and mCherry expression 
(red) in cells treated as in F. Bars, 10 µm.
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IR that are not expected to induce apoptosis had little effect in 
the absence of Chk1 inhibition (Fig. S1 E). Importantly, HeLa 
cells transiently transfected with the full-length caspase-2 BiFC 
components also formed caspase-2 BiFC puncta in the nucleo-
lus in response to camptothecin, albeit with reduced efficiency, 
further underscoring the enhanced sensitivity of the stable re-
porter (Fig. S1 F). Together, these results suggest that DNA 
damage can induce the assembly of activation platforms that 
recruit caspase-2 in at least two distinct compartments in the 
cell: the nucleolus and the cytoplasm.
Caspase-2 activation in the nucleolus
To verify that the localization of caspase-2 BiFC represented 
the activity of the endogenous caspase-2 protein, we fraction-
ated cells into cytoplasmic, nuclear, and nucleolar fractions. 
Full-length caspase-2 was detected in all three fractions, and 
caspase-2 cleavage was detected in the cytosol after camptoth-
ecin treatment (Fig. 2 A). In the nucleolus, increased doses of 
camptothecin resulted in disappearance of full-length caspase-2 
and the concomitant appearance of the p35 and p20 cleavage 
fragments. Caspase-3 was detected only in the cytoplasmic 
fraction (Fig. 2 B). Therefore, the caspase-2 cleavage detected 
is unlikely to be a result of caspase-3–mediated cleavage. These 
results are consistent with our findings that caspase-2 activation 
platforms assemble in the nucleolus in response to DNA dam-
age, unveiling a novel site for caspase-2 activation.
We used colocalization and 3D imaging to more clearly 
visualize where caspase-2 is activated within the cell. We ex-
pressed mTurquoise-tagged versions of Histone H2A and actin 
to identify the nuclear and cytoplasmic regions, respectively. 
Fig. 3 A shows representative images of camptothecin-treated 
cells with caspase-2 BiFC in the cytoplasm, nucleus, and nu-
cleolus in relation to these markers. Caspase-2 contains a clas-
sic nuclear localization sequence (NLS) in its prodomain (aa 
131–138; Baliga et al., 2003). To determine whether the NLS 
is required for nucleolar caspase-2 BiFC, we compared cells 
transfected with the C2-Pro BiFC pair that contains the NLS 
and a C2-CARD BiFC pair that lacks the NLS, constructs that 
behave identically in cells exposed to heat shock (Bouchi-
er-Hayes et al., 2009). After treatment with camptothecin, there 
was a significant decrease in the amount of C2 CARD-BiFC in 
the nucleolus compared with the C2 Pro-BiFC reporter contain-
ing the NLS (Fig. 3, B and C). This indicates that recruitment of 
caspase-2 to the nucleolus is not just a CARD-specific event but 
is highly dependent on the NLS.
Next, we determined where caspase-2 BiFC localized in 
cells with DNA double-strand breaks using 53BP1–teal fluores-
cent protein (TFP), a fusion protein of the p53 binding protein 
1 (53BP1) that localizes to double-strand breaks and lacks the 
functional domains of 53BP1 (Dimitrova et al., 2008). We ex-
pressed 53BP1-TFP in Hela.C2 pro-BiFC cells and analyzed 
the subcellular localization of caspase-2 BiFC in cells with 
and without 53BP1 fluorescent DNA damage foci. There was 
a strong correlation between the appearance of caspase-2 BiFC 
in the nucleolus and the appearance of 53BP1 foci, even in cells 
treated with etoposide (P = 1.61 × 10−3), which induces minimal 
nucleolar caspase-2 BiFC (Fig. 3, D and E). This suggests that 
caspase-2 activation in the nucleolus is a direct response to the 
presence of DNA damage.
The nucleolus consists of three compartments: the fibrillar 
center (FC), the dense fibrillar center (DFC), and the granular 
component (GC). To more precisely determine the compartment 
where caspase-2 is predominantly activated, we expressed CFP-
tagged versions of fibrillarin, which localizes to the DFC; nu-
cleolin (NCL), which localizes to the GC and DFC; and NPM1, 
which localizes to the GC. Using 3D imaging, we found that the 
nucleolar caspase-2 BiFC signal, represented by one or more 
distinct puncta, was encapsulated by these various markers, 
with signals for NPM1 and NCL closely adjacent to the circum-
ference of the BiFC signal (Fig. 4 A, Fig. S2 A, and Video 1). 
This suggests that caspase-2 activation platforms assemble pre-
dominantly in the FC and the internal boundary of the surround-
ing GC. Interestingly, the assembly of the caspase-2 activation 
platform appeared to induce changes in the organization of 
NPM1 and NCL, from being diffuse throughout the nucleolus 
in untreated cells to appearing as a ring around the caspase-2 
BiFC complex in camptothecin-treated cells. Analysis of the lo-
calization of the NPM1 signal or the NCL signal relative to the 
C2 BiFC signal confirms this, showing that NPM1 and NCL re-
distributed with treatment to form a pocket where the caspase-2 
activating complex resided, in contrast to fibrillarin, which did 
not change its distribution (Fig. 4 B and Fig. S2, B and C).
Nucleolar caspase-2 activation is driven by 
the PIDDosome
Next, we determined the components of the activation platform 
that assembled in the nucleolus by investigating the roles of 
the known PIDDosome proteins, PIDD and RAI DD. We stably 
expressed the bicistronic C2 Pro-BiFC vector in litter-matched 
Raidd+/− and Raidd−/−, as well as litter-matched Pidd+/+ and 
Pidd−/−, E1A/Ras transformed mouse embryonic fibroblasts 
(MEFs). For each pair of cell lines, we sorted on mCherry flu-
orescence to select for matched lines expressing equal levels 
Figure 2. Caspase-2 is cleaved in the nucleolus. (A) HeLa cells treated 
with or without camptothecin (0, 50, 100, or 200  µM) for 16  h were 
fractionated into the cytosol, nucleoplasm, and nucleolus and immuno-
blotted for caspase-2, GAP DH (cytosol), or fibrillarin (nucleolus). (B) HeLa 
cells treated with or without camptothecin (200 µM) for 16 h were frac-
tionated into the cytosol and nucleolus and immunoblotted for caspase-3, 
caspase-2, or fibrillarin (nucleolus).
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of the linked caspase-2 BiFC reporter (Fig. S3, A and B). 
Raidd+/− and Pidd+/+ MEFs both engaged caspase-2 BiFC in the 
cytoplasm, nucleus, and nucleolus in response to the DNA-dam-
aging agents, whereas nucleolar caspase-2 BiFC was not de-
tected in response to vincristine. Deletion of Raidd completely 
blocked the ability of each of the genotoxic drugs to induce 
caspase-2 BiFC (Fig. 5, A and B; and Fig. S3 C). This demon-
strates that RAI DD is required for caspase-2 BiFC and hence 
caspase-2 induced proximity in all three cellular compartments. 
Surprisingly, we found that PIDD was dispensable for cytosolic 
or nuclear caspase-2 activation in response to all drugs tested 
(Fig. 5 C). In striking contrast, PIDD was essential for the DNA 
damage–induced nucleolar BiFC component (Fig. 5, C and D; 
and Fig. S3 D). These MEF data were confirmed in HeLa.C2 
Pro-BiFC cells bearing RAI DD- or PIDD-null alleles generated 
by CRI SPR/Cas9 as well as siRNA-mediated silenced PIDD 
(Fig. 5 E and Fig. S3, E and F). An essential role for PIDD in 
nucleolar caspase-2 activation was also observed in response 
to IR plus Chk1i in MEFs, and in this context, the gene’s re-
quirement extended from nucleolar BiFC to the cytoplasmic 
compartment (Fig. 3 F). These results indicate that the nucleo-
lus is the predominant site for PIDDosome-mediated caspase-2 
activation in response to DNA damage.
PIDD interacts with the nucleolar resident 
protein NPM1
Having identified the nucleolus as a novel site for PIDDosome 
signaling, we set out to explore the mechanisms underlying 
platform recruitment to this organelle. Ongoing proteomic 
analyses of Flag-PIDD immunoprecipitates detected six 
Figure 3. Caspase-2 activation in the nucleolus re-
quires the NLS and is a response to DNA breaks. (A) 
3D reconstructions of HeLa.C2 Pro-BiFC cells trans-
fected with Histone H2A-mTurquoise or Actin-mTur-
quoise and treated with camptothecin (100 µM) plus 
qVD-OPH (20  µM) were composed from 0.2-µm se-
rial confocal images through the z-plane of the cell. 
Representative orthogonal-slice views show cells (red) 
with caspase-2 BiFC (yellow) and the indicated co-
expressed proteins (blue). The middle, right, and top 
panels are the xy, yz, and xz planes, respectively. The 
yz and xz planes intersect according to the crosshairs. 
Bars, 10 µm. (B) HeLa cells transfected with the C2-Pro 
(1–147) BiFC or the C2-CARD (1–109) BiFC plasmid 
pair (25, 50, or 100 ng of each) with Histone H2B 
RFP (50 ng) were treated with or without camptothe-
cin (100 µM). Cells were assessed 24 h later for the 
percentage of RFP-positive transfected cells that were 
Venus+ in the nucleolus, nucleus, or cytoplasm deter-
mined from at least 30 microscopy images per well. 
Results are the mean of three independent experiments 
± SD. *, P < 0.05; **, P < 0.005 determined from 
the percentage of Venus-positive cells in the nucleolus. 
(C) Representative confocal images show caspase-2 
BiFC (yellow) and nuclear Histone H2B expression 
(red) in cells treated as in B. Bars, 20 µm. (D) HeLa.
C2 Pro-BiFC cells transfected with 53BP1-TFP (2 µg) 
were treated with the indicated drugs (100 µM) plus 
qVD-OPH (20  µM). TFP-positive cells were counted 
for absence or presence of 53BP1 foci and the per-
centage of cells that were Venus+ in the nucleolus, 
nucleus, or cytoplasm. Results are the mean of three 
independent experiments ± SD. The association of 
cells with caspase-2 BiFC in the nucleolus and 53BP1 
foci was significant across experiments (camptothecin, 
P = 7.58 × 10−6; topotecan, 3.06 × 10−7; etoposide, 
1.61 × 10−3) as calculated by the Cochran–Mantel–
Haenszel test. (E) Representative confocal images of 
cells treated as in D show 53BP1 (blue) and caspase-2 
BiFC (yellow). Bars, 5 µm.
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unique peptides derived from NPM1 (Table S1). The spatial 
vicinity between NPM1 and caspase-2 BiFC within the nucle-
olus, including the close association of signals (Fig. 4, A and 
B), prompted us to ask whether endogenous PIDD and NPM1 
physically interact in cells exposed to DNA damage. An in-
teraction between the two proteins was readily detected in re-
ciprocal NPM1 and PIDD pulldowns from cells treated with 
camptothecin, but not (or less so) in untreated cells or cells 
treated with actinomycin D (which failed to trigger caspase-2 
BiFC; Fig. 6, A and B; and Fig. 1 A). An endogenous interac-
tion between NPM1 and PIDD was also observed in response 
to IR plus Chk1i, as detected in PIDD or NPM1 immunopre-
cipitates obtained with multiple antibodies (Fig. 6, C and D; 
and Fig. S4 A). Thus a PIDDosome component, PIDD, and 
a nucleolar protein, NPM1, physically interact in response 
to DNA-damaging stimuli that trigger nucleolar and PIDDo-
some-dependent caspase-2 BiFC.
Full-length PIDD is constitutively autoprocessed into 
three fragments termed PIDD-N, PIDD-C, and PIDD-CC 
(Fig.  6  F). Of these, only PIDD-CC can bind RAI DD and 
mobilize the caspase-2–activating PIDDosome (Tinel and 
Tschopp, 2004; Tinel et al., 2007). PIDD-C anchors the 
pro-survival PIDD-RIP1-NEMO PIDDosome (Janssens et al., 
2005), whereas PIDD-N serves an as-yet-uncharacterized reg-
ulatory role (Tinel et al., 2007). Transfections with Flag-PIDD 
deletion constructs identified the leucine-rich repeats (LRR) 
domain on PIDD-N as sufficient for NPM1 binding (Fig. 6 G). 
NPM1 docking onto PIDD-N was antagonized by the proximal 
ZO-1 and UNC5-like (ZU-5) domain, whose deletion restored 
full NPM1 binding to PIDD-N (Fig. 6 G, lane 5). Pulldowns 
with a specific N-terminal PIDD antibody (S-17; Fig. S4 C) 
confirmed the NPM1-PIDD-N interaction at the endogenous 
level (Fig. 6, H and I). Importantly, NPM1 also interacts with 
PIDD-CC at the endogenous level. This is evident from the 
analysis of NPM1 pulldowns, which contain both PIDD-N and 
PIDD-CC (Fig. 6, A, D, and I). An NPM1–PIDD-CC interac-
tion is further supported by the presence of NPM1 in PIDD 
immunoprecipitates containing PIDD-C and PIDD-CC, but 
not PIDD-N or PIDD-FL (see PIDD IPs with C-terminal an-
tibodies Anto1 and AL233 in Fig. 6, B and C, and Fig. S4 A). 
Overall, these experiments identify two NPM1 binding sites 
on PIDD, enabling interactions with both PIDD-N (via the 
LRR domain) and PIDD-CC.
Similar mapping experiments exploiting HA-NPM1 dele-
tion constructs (Korgaonkar et al., 2005) identified the central 
region (CR; spanning aa 117–187) as the PIDD binding site 
on NPM1 (Fig. 6, E and J). The CR contains conserved acidic 
tracts and has been implicated in histone binding yet remains 
largely uncharacterized (Grisendi et al., 2006; Mitrea and Kri-
wacki, 2013). PIDD binding to the CR assigns a new functional 
role for this domain. These experiments identify NPM1 as a 
PIDD interaction partner in the nucleolus.
Figure 4. Localization of caspase-2 activa-
tion platforms within the nucleolus. (A) HeLa.
C2 Pro-BiFC cells transfected with Fibrillar-
in-CFP (2 µg), TFP-Nucleolin (NCL; 2 µg), or 
TFP-NPM1 (2 µg) were treated with or without 
camptothecin (10 µM) plus qVD-OPH (20 µM). 
Representative images show cells (red) with 
caspase-2 BiFC (yellow) and the indicated 
nucleolar proteins (blue). Bars, 10 µm. 3D 
reconstructions of the white boxed region 
composed from 0.2-µm serial confocal images 
through the z-plane of the cell are shown as or-
thogonal-slice views (right). The middle, right, 
and top panels are the xy, yz, and xz planes, 
respectively. The yz and xz planes intersect ac-
cording to the crosshairs. Bars, 2 µm. (B) 3D 
graphs of pixel intensities of TFP-NPM1 and 
C2-BiFC signals in a representative untreated 
and camptothecin-treated cell.
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NPM1 is required for PIDDosome signaling 
in the nucleolus
Next, we asked whether NPM1 is required for PIDDosome sig-
naling. SiRNA-mediated silencing of NPM1 in HeLa.C2 Pro-
BiFC cells substantially reduced the levels of caspase-2 BiFC 
in the nucleolus in response to camptothecin compared with 
control cells but had no effect on total caspase-2 BiFC or the 
size or morphology of the nucleoli (Fig. 7, A and B; and Fig. S5 
A). This result was very similar to the effect of PIDD deficiency 
on nucleolar caspase-2 BiFC (Fig.  5, C and E). In response 
to IR plus Chk1i, we also observed a reduction in nucleolar 
caspase-2 BiFC (Fig. 7 C) in addition to a reduction in overall 
caspase-2 BiFC. These data identify a critical role for NPM1 in 
DNA damage–induced nucleolar PIDDosome signaling. In the 
Figure 5. RAI DD is required for caspase-2 BiFC, but PIDD is required for caspase-2 BiFC only in the nucleolus. (A) Litter-matched Raidd+/− or Raidd−/− MEFs 
stably expressing C2 Pro-BiFC were treated with camptothecin (250 nM), irinotecan (250 nM), topotecan (250 nM), etoposide (250 nM), or vincristine 
(25 nM) plus qVD-OPH (20 µM). The percentage of cells that were Venus+ in the nucleolus, nucleus, or cytoplasm was determined at 24 h from at least 
30 microscopy images per well. Results are the mean of three independent experiments ± SD. The differences in total Venus-positive cells between the 
Raidd+/− and Raidd−/− groups is significant to P = 0.0034. (B) Representative confocal images show caspase-2 BiFC (yellow) and mCherry expression (red) 
in Raidd+/− and Raidd−/− C2 Pro-BiFC MEFs. Bars, 5 µm. Arrowheads indicate locations of nucleoli that are magnified in the bottom panel (bars, 1 µm). 
See Fig. S3 C for full dataset images. (C) Litter-matched Pidd+/+ or Pidd−/− MEFs stably expressing C2 Pro-BiFC were treated with camptothecin (250 nM), 
irinotecan (250 nM), topotecan (250 nM), etoposide (250 nM), or vincristine (25 nM) plus qVD-OPH (20 µM). The percentage of cells that were Venus+ 
in the nucleolus, nucleus, or cytoplasm was determined at 24 h from at least 30 microscopy images per well. Results are the mean of three independent 
experiments ± SD. *, P < 0.05; **, P < 0.005 determined from the percentage of nucleolar Venus-positive cells between Pidd+/+ and Pidd−/− cells for 
each treatment. (D) Representative confocal images show caspase-2 BiFC (yellow) and mCherry expression (red) in Pidd+/+ and Pidd−/− C2 Pro-BiFC MEFs. 
Bars, 5 µm. Arrowheads indicate locations of nucleoli that are magnified in the lower panel (bars, 1 µm). See Fig. S3D for full dataset images. (E) PIDD 
or RAI DD was deleted from HeLa.C2 Pro-BiFC cells with CRI SPR/Cas9 using two independent sgRNAs per gene. The percentage of cells treated with or 
without camptothecin (100 µM) plus qVD-OPH (20 µM) that were Venus+ in the nucleolus, nucleus, or cytoplasm was determined after 24 h from at least 
50 microscopy images per well. Results are the mean of three independent experiments ± SD. *, P < 0.05 determined from the percentage of nucleolar 
Venus-positive cells compared with the control treated group. The difference in total Venus-positive cells compared with camptothecin-treated control for 
ΔRAI DD cells is significant to P < 0.0001 (ΔRAI DD(57)) and P = 0.0187 (ΔRAI DD(76)). (F) Pidd+/+ and Pidd−/− C2-Pro BiFC MEFs were treated with or 
without Gö6976 (0.125, 0.25, or 0.5 µM) ± IR (10 Gy) plus qVD-OPH (20 µM). The percentage of cells that were Venus+ in the nucleolus, nucleus, or 
cytoplasm was determined 24 h after treatment from at least 50 microscopy images per well. Results represent triplicate counts ± SD. *, P < 0.05; **, P < 
0.005 determined from the percentage of Venus-positive cells in the nucleolus between Pidd+/+ and Pidd−/− cells for each treatment.
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context of IR plus Chk1i, the requirement for NPM1 appears 
to extend to all cellular PIDDosomes, a seemingly surprising 
observation for a predominantly nuclear protein. However, cells 
treated with IR plus Chk1i showed an unusual distribution of 
NPM1: in many cells, the nuclei were highly fragmented, with 
NPM1 accumulating in micronuclei in addition to the nucleus 
and nucleolus, compared with camptothecin-treated cells, in 
which NPM1 accumulated only in the nucleus and nucleolus 
(Fig. S5 B). Thus the cytoplasmic caspase-2 BiFC that is de-
pendent on NPM1 is likely caused by the fragmentation of the 
nucleus and nucleolus dispersing the localization of NPM1.
To confirm the requirement of NPM1 for caspase-2 ac-
tivation in response to IR plus Chk1i or camptothecin, we as-
sessed caspase-2 processing in multiple mammalian cell types 
including NPM1-depleted PC3, HCT-116, and HeLa cell lines, 
as well as Npm1−/− MEFs (Fig. 7, D–F; and Fig. S5, C and D). 
In all cases, reduction or loss of NPM1 reduced or completely 
blocked caspase-2 cleavage. Importantly, knockdown or loss of 
NPM1 did not affect the expression levels of any PIDDosome 
component, nor did it affect ATM-mediated phosphorylation of 
PIDD on Thr788, the initiating step in PIDDosome assembly 
after IR plus Chk1i (Fig. 7, D and F; Ando et al., 2012).
Figure 6. NPM1 interacts with PIDD-CC and PIDD-N after DNA damage. (A) HeLa cells treated with DMSO, actinomycin D (Act-D; 500 nM) or camptoth-
ecin (CPT; 200 µM) were harvested 24 h after treatment, lysed, and immunoprecipitated (IP) with NPM1 antibody. Immunoprecipitates were analyzed by 
Western blot (IB). (B) HeLa cells treated with DMSO, Act-D (500 nM), or CPT (200 µM) were harvested 24 h after treatment, lysed, and immunoprecipitated 
with monoclonal Anto-1 antibody to PIDD C terminus. Immunoprecipitates were analyzed by Western blot. (C) HeLa cells treated with or without Gö6976 
(1 µM) ± IR (10 Gy) were harvested 24 h after IR, lysed, and immunoprecipitated with monoclonal anti-PIDD antibody. Immunoprecipitates were analyzed 
by Western blot. (D) HeLa cells treated with or without Gö6976 (1 µM) ± IR (10 Gy) were harvested 24 h after IR, lysed, and immunoprecipitated with 
anti-NPM1 antibody. Immunoprecipitates were analyzed by Western blot. (E) Schematic representation of NPM1 (WT) and NPM1c+ (mutated in AML) 
protein domain structure. Indicated are amino acids defining the extremities of deletion constructs used in J. OD/ChD, oligomerization/chaperone domain; 
D/RBD, DNA/RNA binding domain; Aro, aromatic region; NuLS, nucleolar localization signal; NES, nuclear exclusion signal. (F) Schematic representa-
tion of PIDD-FL, PIDD autocleavage products. Indicated are amino acids defining the extremities of deletion constructs used in G and autocleavage sites in 
PIDD. LRR, LRR domain; ZU-5, ZO-1 and UNC5-like; UPA, uncharacterized protein domain in UNC5, PIDD, and Ankyrin family of proteins (designates the 
putative PIDD oligomerization domain; Janssens and Tinel, 2012). (G) HeLa cells transfected with the indicated Flag-PIDD constructs were harvested 24 h 
after transfection. Flag immunoprecipitates were analyzed by Western blot. (H) HeLa cells treated with DMSO, Act-D (500 nM), or CPT (200 µM) were 
harvested 24 h after treatment, lysed, and immunoprecipitated with S-17 antibody to PIDD N terminus. Immunoprecipitates were analyzed by Western blot. 
ns, nonspecific band. (I) HeLa cells treated with DMSO, Act-D (500 nM), or CPT (200 µM) were harvested 24 h after treatment, lysed, and immunoprecip-
itated with NPM1 antibody. Immunoprecipitates were analyzed by Western blot. (J) HeLa cells cotransfected with the indicated HA-NPM1 constructs and 
the noncleavable mutant form of PIDD were harvested 24 h after transfection. HA immunoprecipitates were analyzed by Western blot.
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We then tested the effects of the NPM1c+ mutation, found 
in 30–50% of patients with adult AML (Falini et al., 2005). This 
four-base insertion at the 3′ end of the NPM1 coding sequence 
converts a nucleolar localization signal into a nuclear export 
signal but does not otherwise affect the protein’s sequence or 
its ability to oligomerize (Fig. 6 E; Falini et al., 2005; Gris-
endi et al., 2005). Thus in NPM1c+ heterozygous AML cells, 
all NPM1 protein (wild-type [WT] and mutant) relocates from 
the nucleolus into the cytoplasm, providing a setting in which 
to investigate the unique consequences of loss of nucleolar 
NPM1. NPM1c+ cells failed to engage caspase-2 cleavage 
after IR plus Chk1i, similar to NPM1-depleted or -knockout 
cells (Fig.  7  G). Thus, not only does NPM1 specifically or-
chestrate nucleolar PIDDosome signaling (Fig.  7, A–C), but 
such nucleolar signaling is also critical to overall PIDDosome 
activity after DNA damage.
Nucleolar PIDDosome signaling contributes 
to PIDDosome-mediated apoptosis
To investigate the significance of nucleolar PIDDosome signal-
ing, we analyzed the effects of caspase-2, PIDD, RAI DD, or 
NPM1 loss on the apoptotic response to DNA damage. We noted 
a significant reduction in cell death in cells exposed to camptoth-
ecin in caspase-2–, RAI DD-, and PIDD-deficient MEFs (Fig. 8, 
A–C). Npm1−/− MEFs were also highly resistant to apoptosis 
induced by camptothecin, irinotecan, and IR plus Chk1i (Fig. 8, 
D and E; and Fig. S5 E). Npm1-depleted HeLa cells also showed 
significant resistance to IR plus Chk1i (Fig. 8 F). The latter form 
Figure 7. NPM1 is required for PIDDosome signaling. (A) HeLa.C2 Pro-BiFC cells were transfected with the indicated siRNAs in the presence of qVD-
OPH (20 µM). 48 h later, cells were treated with or without camptothecin (100 µM). The percentage of cells that were Venus+ in the nucleolus, nucleus, 
or cytoplasm was determined at 24 h from at least 50 microscopy images per well. Results are the mean of three independent experiments ± SD. *, P < 
0.05. (B) Representative confocal images show caspase-2 BiFC (yellow) and mCherry expression (red) from cells treated as in A. Bars, 10 µm. (C) HeLa.
C2 Pro-BiFC cells transfected with the indicated siRNAs in the presence of qVD-OPH (20 µM) for 48 h were treated with or without IR (50 Gy) ± Gö6976 
(1 µM). The percentage of cells that were Venus+ in the nucleolus, nucleus, or cytoplasm was determined at 24 h from at least 50 microscopy images per 
well. Results are the mean of four independent experiments ± SD. ***, P < 0.0005. (D) Tp53−/− MEFs of indicated Npm1 genotypes were treated with or 
without Gö6976 (1 µM) ± IR (10 Gy) and harvested 24 h later. Lysates were analyzed by Western blot. (E) Tp53−/− MEFs of indicated Npm1 genotypes 
were treated with or without camptothecin (100 or 150 µM) and harvested 24 h later. Lysates were analyzed by Western blot. (F) PC3 cells transfected 
with the indicated siRNAs were treated with or without Gö6976 (1 µM) ± IR (10 Gy) and harvested 24 h later. Lysates were analyzed by Western blot. 
(G) OCI-AML2 and OCI-AML3 cells, of indicated NPM1 genotypes, were treated with or without Gö6976 (1 µM) ± IR (10 Gy) and harvested 24 h later. 
Lysates were analyzed by Western blot.
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of cell death depends on the PIDDosome in multiple cell types 
and species (Ando et al., 2012; Manzl et al., 2013; Thompson et 
al., 2015), and this result phenocopies Casp2−/− MEFs (Ho et al., 
2009; Ando et al., 2012). Therefore, the requirement of NPM1 
for caspase-2 cleavage in response to IR plus Chk1i (Fig.  7, 
D–F; and Fig. S5, C and D), appears to be an essential compo-
nent of the resulting apoptosis. To further test this hypothesis, 
we used zebrafish embryos that are devoid of WT p53 (similar 
to the Npm1-deficient MEFs) and thus lack alternative apoptotic 
responses to IR (Sidi et al., 2008; Ando et al., 2012; Thomp-
son et al., 2015). Zebrafish embryos depleted of all endogenous 
NPM1 via combined injections of specific npm1a and npm1b 
morpholinos (Bolli et al., 2010) failed to engage apoptosis in 
response to IR plus Chk1i (compare Fig. 8 H/H′ and Fig. 8 J/J′; 
acridine orange signal quantifications are shown in Fig. 8 K), 
again phenocopying loss of caspase-2 (Sidi et al., 2008).
Numerous studies have shown that deficiency of caspase-2 
increases cell proliferation (Berube et al., 2005; Ho et al., 2009; 
Parsons et al., 2013; Puccini et al., 2013b), suggesting a role 
in regulating cell cycle in addition to inducing apoptosis. To 
explore the role of NPM1 in this phenomenon, we examined 
clonogenic outgrowth in Casp2+/+ and Casp2−/− MEFs treated 
with or without NSC348884, a chemical inhibitor of NPM1 
that disrupts a defined hydrophobic pocket of NPM1 required 
for oligomerization (Qi et al., 2008). As expected, we observed 
increased cell growth of Casp2−/− cells compared with the WT 
cells. Inhibition of NPM1 resulted in increased growth of the 
Casp2+/+ cells but had no effect when caspase-2 was absent 
(Fig. 8, L and M). Thus we conclude that NPM1-driven nucle-
olar PIDDosome signaling is critical to PIDDosome-mediated 
cell cycle regulation and apoptosis in response to DNA damage.
Discussion
The PIDDosome was characterized more than a decade ago as 
an activation platform that assembles in response to genotoxic 
stress to recruit and activate caspase-2 (Tinel and Tschopp, 
2004). Since then, there have been no robust descriptions of al-
ternative activation platforms for caspase-2. Nonetheless, there 
has been some controversy over the requirement of PIDD for 
caspase-2 activation (Bock et al., 2012; Bouchier-Hayes and 
Green, 2012). The data presented here indicate that the PIDD 
requirement for caspase-2 activation depends on not only the 
type of caspase-2–activating stimulus, but also where it is ac-
tivated in the cell. Moreover, our results support a model in 
which NPM1 forms a scaffold for PIDDosome assembly in the 
nucleolus in response to DNA damage (Fig. 9).
It has been reported that caspase-2 activation can pro-
ceed normally in cells from PIDD-deficient mice (Manzl et al., 
2009). PIDD-knockout mice also fail to phenocopy the tumor 
acceleration effects of caspase-2 deficiency in the Eµ-Myc 
model (Manzl et al., 2012). These observations have challenged 
the importance of PIDD for caspase-2 activation and function. 
In MEFs or human cells with reduced Chk1 or BubR1 dosage, 
however, caspase-2 activation in response to IR is completely 
dependent on PIDD (Ando et al., 2012; Thompson et al., 2015). 
Thus these different observations may be caused by varying 
levels of the PIDDosome’s endogenous inhibitors. However, 
the possibility that distinct activation platforms for caspase-2 
exist had not been thoroughly explored. Using a highly sensitive 
and specific method to visualize caspase-2 activation platform 
assembly, we show that PIDD is required only for the propor-
tion of cells that induce caspase-2 activation platform assembly 
in the nucleolus in response to many DNA-damaging agents. 
Therefore, we propose a model in which at least two distinct 
activation platforms for caspase-2 exist: one in the nucleolus 
that requires PIDD, and one in the cytoplasm or nucleus that is 
PIDD independent (Fig. 9).
Although this is the first evidence that caspase-2 is acti-
vated in the nucleolus, the presence of caspase-2 in the nucleus 
has been reported by several groups. Because of the NLS in the 
prodomain of caspase-2, GFP-tagged caspase-2 prodomain lo-
calizes to the nucleus upon overexpression (Baliga et al., 2003), 
and immunostaining for endogenous caspase-2 shows accumu-
lation in nucleus, cytosol, and Golgi apparatus (Mancini et al., 
2000). However, our previous results using the caspase-2 BiFC 
reporter showed no caspase-2 activation in the nucleus in re-
sponse to heat shock (Bouchier-Hayes et al., 2009). In addition, 
a specific role for caspase-2 activation in the nucleus has not 
been described. In contrast to our previous results, our results 
here show some caspase-2–induced proximity in the nucleus, 
distinguishable from nucleolar and cytoplasmic BiFC signals. 
This is likely because of the enhanced sensitivity of the stably 
expressed caspase-2 BiFC reporter, which ensures equal ex-
pression of both BiFC components, hence reducing false-neg-
ative results caused by the preferential recruitment of one of 
the components to the platform. However, the levels of nuclear 
caspase-2 BiFC varied greatly between experiments. It is there-
fore unclear whether the nuclear caspase-2 BiFC represents an 
independent caspase-2 activation platform or is contiguous with 
the cytosolic platform. Given that both are RAI DD dependent 
and PIDD independent, we suggest that this represents the dy-
namic nature of the cytosolic platform. The nucleolar complex, 
on the other hand, appears distinct, as it is dependent on PIDD 
and NPM1 for its assembly.
The existence of a unique activation platform that assem-
bles in the nucleolus to recruit caspase-2 suggests that this nu-
cleolar complex may also have distinct functions. Traditionally 
known as the cell’s ribosome factory, the nucleolus has recently 
emerged as a complex organelle with multiple nonribosomal 
functions. This long list of functions includes apoptosis, cell 
proliferation, regulation of protein stability, tumor surveillance, 
telomere metabolism, and DNA damage repair (Antoniali et 
al., 2014). Nucleolar structure is often compromised in cancer 
cells, resulting in increased nucleolar size and number (Pianese, 
1896). A clear difference in the caspase-2 requirement for apop-
tosis between transformed cells and primary cells has been re-
ported: transformed caspase-2–deficient embryonic fibroblasts 
were robustly resistant to IR-induced apoptosis, whereas the 
primary cells were not (Ho et al., 2009). Thus, it is possible 
that the increased size and number of nucleoli provides more 
ample sites for caspase-2 activation in cancer cells. The primary 
role of NPM1 is thought to be in ribosome biogenesis, function-
ing as a nuclear chaperone that shuttles between the cytoplasm 
and nucleus (Lindström, 2011). However, it is also a strong 
tumor suppressor and has important roles in regulating cell 
cycle and cell survival. Knockout of Npm1 in mice is embry-
onic lethal, and Npm1 haploinsufficiency leads to uncontrolled 
centrosome duplication, resulting in aneuploidy, genomic in-
stability, and acceleration of Eµ-Myc–driven lymphomagenesis 
(Grisendi et al., 2005).
Our results suggest that NPM1-driven activation of 
caspase-2 is a key initiator of the apoptotic pathway. However, 
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the specific role of NPM1 in apoptosis is unclear. Inhibition of 
NPM1 has been shown to induce apoptosis or sensitize cells to 
apoptosis (Colombo et al., 2005; Grisendi et al., 2005; Cullen et 
al., 2009; Balusu et al., 2011). This is thought to be caused by 
an inhibitory effect on p53 activity by NPM1, since knockout 
of p53 rescues apoptosis as a result of NPM1 deficiency (Co-
lombo et al., 2005). We have shown that when p53 is absent, 
loss of NPM1 profoundly protects against apoptosis induced 
by topoisomerase I inhibition or IR plus Chk1i (Fig. 8, D–J). 
However, using different experimental systems, NPM1 has also 
Figure 8. Inhibition of NPM1 blocks apoptosis and caspase-2–dependent suppression of cell growth. (A–C) Litter-matched Casp2+/+ and Casp2−/− MEFs 
(A), Raidd+/+ and Raidd−/− MEFs (B), or Pidd+/+ and Pidd−/− MEFs (C) were treated with or without camptothecin (250 nM). Apoptosis was assessed by flow 
cytometry for Annexin V binding 16 h later. Results are the mean of three to four independent experiments ± SD. *, P < 0.05. (D) Tp53−/− MEFs of indicated 
Npm1 genotypes were treated with or without camptothecin. Apoptosis was assessed by flow cytometry for Annexin V binding 16 h after treatment. Results 
are the mean of three independent experiments ± SD. *, P < 0.05; **, P < 0.005. (E) Tp53−/− MEFs of indicated Npm1 genotypes were treated with or 
without Gö6976 (1 µM) ± IR (10 Gy), harvested 24 h after IR, stained for TUN EL, and analyzed by flow cytometry. Results are the mean of three indepen-
dent experiments ± SD. *, P < 0.05. (F) HeLa cells transfected with the indicated siRNAs were treated with or without Gö6976 (1 µM) ± IR (10 Gy) and 
stained with alamarBlue 72 h after IR. Results are the mean of three independent experiments ± SD.*, P < 0.05 (two-tailed Student’s t test). (G–J′) p53M214K/
M214K zebrafish embryos were injected at the one-cell stage with standard control (ctrl) or npm1a+npm1b morpholinos, incubated 17 h later with or without 
Gö6976 at indicated concentrations (μM), treated with or without 15 Gy IR, and stained with the cell death marker acridine orange (AO) after 7 h. All 
embryos were imaged live at 24 h postfertilization. Panels G′, H′, I′, and J′ are blowups of indicated spinal cord areas in corresponding whole-embryo 
panels. Bars, 250 µm. (K) Quantification of AO stains shown in G–J′. Results are the mean of three independent experiments (≥10 embryos per condition) 
± SEM. **, P < 0.005. (L) Litter-matched Casp2+/+ and Casp2−/− MEFs, plated at low density, were treated with or without a chemical inhibitor of NPM1 
(3 µM) for 7 h. Colonies were stained with methylene blue 5 d after treatment. The number of colonies under each treatment condition is shown. Results 
are the mean of six individual wells across two independent experiments ± SD. **, P < 0.005; ***, P < 0.0005. (M) Representative images of methylene 
blue–stained colonies from cells treated as in L.
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been shown to enhance p53 stability and activity (Colombo et 
al., 2002). Therefore it remains possible that NPM1-induced 
caspase-2 activation can engage p53 to induce apoptosis.
In addition to apoptosis, caspase-2 has been implicated 
in the regulation of cell proliferation. Loss of caspase-2 has 
been associated with higher proliferation rates, and caspase-2 
has been observed to induce cell cycle arrest after DNA dam-
age (Ho et al., 2009). Our data indicate that the caspase-2–
associated inhibition of cell proliferation is dependent on 
NPM1, further underscoring a biological role for the caspase-2 
nucleolar complex. Loss of caspase-2 has also been associated 
with telomere shortening (Dorstyn et al., 2012) and increased 
genomic instability (Dorstyn et al., 2012; Parsons et al., 2013). 
Thus, there is considerable overlap between the nonribosomal 
functions of the nucleolus and NPM1 with some of the putative 
functions of caspase-2. Therefore, the nucleolus may provide a 
site for PIDDosome assembly to initiate the caspase-2 activa-
tion cascade, resulting in regulation of both its proapoptotic and 
nonapoptotic functions.
The assembly of the PIDDosome in the nucleolus, as me-
diated by NPM1, is likely to provide activated caspase-2 ac-
cess to a set of substrates distinct from those available in the 
cytosol. Very few verified substrates for caspase-2 exist, the 
most well-characterized being the BH3-only Bcl-2 protein, Bid. 
Although cleavage of Bid is considered the primary route to 
apoptosis by caspase-2 (Guo et al., 2002; Bonzon et al., 2006), 
Bid-deficient cells do not phenocopy caspase-2–deficient 
cells with respect to DNA damage–induced cell cycle arrest 
(Kaufmann et al., 2007) and tumor suppression (Manzl et al., 
2012). Therefore, additional caspase-2 substrates are likely to 
exist. Many of the proteomic screens to identify caspase sub-
strates have focused primarily on proteins in the cytosol (Wejda 
et al., 2012) and may not have been able to identify substrates 
that reside in the nucleolus or substrates that are cleaved in the 
nucleolus. Our results suggest that interrogating the nucleolar 
proteome may identify novel caspase-2 substrates. For exam-
ple, MDM2 is a caspase-2 substrate that is sequestered in the 
nucleolus by p19ARF to help promote p53 stabilization in re-
sponse to IR (Weber et al., 1999). Cleavage by caspase-2 is pro-
posed to produce a fragment of MDM2 that can bind to p53 but 
does not degrade it (Oliver et al., 2011). NPM1 acts to tether 
ARF to the nucleolus, which is required to maintain ARF sta-
bility (Bertwistle et al., 2004; Colombo et al., 2005). Thus the 
proximity of the caspase-2 activation platform to its substrate 
may facilitate this function of MDM2, promoting the ability of 
nucleolar ARF to induce apoptosis.
In conclusion, we have found that PIDDosome assembly 
in response to DNA damage is highly regulated by the presence 
and localization of NPM1. This complex is primarily assem-
bled in the nucleolus, providing a novel localization for PID-
Dosome assembly. In addition, our data show that caspase-2 
is also recruited to a distinct cytosolic activation platform that 
is PIDD independent while still dependent on RAI DD. These 
data, which provide a model of context-specific regulation of 
caspase-2 by PIDD, may alleviate the controversy surround-
ing the role of PIDD—and by extension the PIDDosome—in 
caspase-2 activation. Importantly, our observations indicate 
that a cytosolic sensor exists that initiates assembly of the 
RAI DD–caspase-2 signaling platform in the cytoplasm. Fur-
ther exploration of this complex is required to both identify this 
sensor and fully understand the functional consequences of this 
PIDD-independent complex.
Materials and methods
Chemicals and antibodies
The following antibodies were used: anti–caspase-2 (clone 11B4; 
EMD Millipore); anti-fibrillarin (C13C3; Cell Signaling Technology); 
anti-GAP DH (Santa Cruz Biotechnology, Inc.); anti–caspase-3 and 
anti–cleaved caspase-3 (9662 and 9664; Cell Signaling Technology); 
anti-NPM1 (clone FC8229, Abcam; clone FC-61991, Thermo Fisher 
Scientific; rabbit anti-NPM1 3542, Cell Signaling Technology); an-
ti-RAI DD (clone 4B12; MBL); anti-PIDD mAbs (AL233 and Anto-1; 
Alexis Biochemicals); anti-PIDD pAbs (clones H-300 and s-17; Santa 
Cruz Biotechnology, Inc.); anti-pPIDD (pT788, as previously described 
[Ando et al., 2012]); anti-Chk2 mAb (clone 7; EMD Millipore), anti–
Flag M2 (Sigma-Aldrich); anti–β-tubulin (2144; Cell Signaling Tech-
nology), and anti-actin (C4; MP Biomedicals). All cell culture media 
reagents were purchased from Invitrogen. Gö6976 was purchased from 
Cell Signaling Technology. Unless otherwise indicated, all other re-
agents were purchased from Sigma-Aldrich.
Plasmids
The pBiFC.VC155 and pBiFC.VN173 plasmids encoding C2 Pro, C2 
CARD, or C2 FL (C320S) were described previously (Bouchier-Hayes 
Figure 9. Model for DNA damage induces caspase-2 activation. Schematic representation of model for two distinct caspase-2 activation platforms that 
assemble in the nucleolus or cytoplasm after DNA damage. See text for details.
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et al., 2009) and are available from Addgene. The bicistronic vector 
consists of C2 Pro-VC and C2 Pro-VN linked with a 2A peptide. 
Silent mutations were introduced into the second C2 Pro nucleotide 
sequence to prevent the sequence recombining out during cloning be-
cause of the presence of two identical C2 Pro sequences. The sequence 
was generated by Bionexus and cloned into pRRL-MND-MCS-2A-
mCherry-2A-Puro. The nucleolar and 53BP1 protein sequences were 
cloned by standard PCR strategies, with primers designed to incor-
porate the appropriate restriction enzyme sites, from cDNA for NCL 
(GFP-Nucleolin, a gift from M. Kastan [Duke University, Durham, NC; 
plasmid 28176; Addgene]); NPM1 (B23(NPM), a gift from M. Dasso 
[National Institutes of Health, Bethesda, MD; plasmid 34553; Ad-
dgene]); and 53BP1 (mCherry-BP1-2-pLPC-puro [plasmid 19835; Ad-
dgene; Dimitrova et al., 2008]) into mTFP-C1 (a gift from R. Campbell 
[University of Alberta, Edmonton, Alberta, Canada] and M. Davidson 
[Florida State University, Tallahassee, FL]). Fibrillarin-CFP was a gift 
from L. Parent (Pennsylvania State University, State College, PA). HA-
NPM1 deletion constructs were provided by D.E. Quelle (University 
of Iowa Carver College of Medicine, Iowa City, IA). Histone H2B 
was purchased from Addgene (plasmid #20972; Addgene; Nam and 
Benezra, 2009). PIDD-deletion constructs were provided by E.  Lo-
gette and J. Tschopp (University of Lausanne, Lausanne, Switzerland). 
mTurquoise-H2A-10 and mTurquoise-Actin-C-18 were gifts from 
M. Davidson (plasmids # 55556 and #55520, respectively; Addgene). 
Each construct was verified by sequencing.
Cell culture and generation of cell lines
Human embryonic kidney (HEK) 293T, U2OS, and HeLa cells were 
grown in DMEM containing FCS (10% [vol/vol]), l-glutamine (2 mM), 
and penicillin/streptomycin (50 IU/50 µg/ml). MEFs were grown in the 
same medium supplemented with sodium pyruvate (1 mM), 1× nones-
sential amino acids, and β-mercaptoethanol (55  µM). Litter-matched 
SV40-transformed Npm1+/+/Tp53−/− and Npm1+/+/Tp53−/− MEFs were a 
gift from P.P. Pandolfi (Beth Israel Deaconess Medical Center, Boston, 
MA). OCI-AML2 (NPM1 WT) and OCI-AML3 (NPM1c+) cells were 
provided by A.  Kentsis (Sloan-Kettering Institute, New York, NY). 
Litter-matched Pidd+/+ and Pidd−/− MEFs were a gift from A. Villunger 
(Innsbruck Medical University, Innsbruck, Austria). Early-passage 
MEFs were simultaneously transduced with frozen supernatants of the 
retroviral expression vectors pBabePuro.H-ras (G12V) and pWZLH.
E1A (provided by S.W. Lowe [Memorial Sloan Kettering Cancer Cen-
ter, New York, NY] and G. Hannon [Cold Spring Harbor Laboratory, 
Cold Spring Harbor, NY]. After 48 h, the cells were harvested by mild 
trypsinization, seeded at 105 cells/well in six-well plates, and cultured 
for 10 d in media containing 0.5 µg/ml puromycin and 40 µg/ml hygro-
mycin for selection of the transduced viruses. Litter-matched Raidd+/− 
and Raidd−/− MEFs were generated and transduced with E1A and Ras 
as previously described (Bouchier-Hayes et al., 2009). Stable cell lines 
were generated by lentiviral transduction. 293T cells were transiently 
transfected with pRRL.C2 Pro-VC-2A-C2 Pro-VN-2A-mCherry 
along with the packaging vector, pSPAX-2, and the envelope vector, 
pVSV-G, using Lipofectamine 2000 transfection reagent (Invitrogen) 
according to manufacturer’s instructions. After 48 h, virus-containing 
supernatants were cleared by centrifugation and incubated with HeLa, 
U2OS, or MEF lines. HeLa and U2OS cells were selected in 1 µg/
ml puromycin followed by FACS for high mCherry expression. The 
HeLa.C2 Pro BiFC clone was generated by single-cell plating of the 
parental cell line, and single-cell clones were screened for induction 
of Venus fluorescence in response to DNA-damaging agents. Raidd+/− 
and Raidd−/− C2 Pro-BiFC MEF and Pidd+/+ and Pidd−/− C2 Pro-BiFC 
MEFs were selected by FACS for equal mCherry expression across 
the matching cell lines.
CRI SPR/Cas9 gene editing
PIDD and RAI DD were deleted from HeLa.C2 Pro-BiFC cells using 
an adaptation of the protocol described in Gundry et al. (2016). Pro-
tospacer sequences for each target gene were identified using the 
CRI SPRscan scoring algorithm (Moreno-Mateos et al., 2015). DNA 
templates for single-guide RNAs (sgRNAs) were made by PCR using 
pX459 plasmid containing the sgRNA scaffold sequence and using 
the following primers: ΔPIDD(76) sequence: 5′-TTA ATA CGA CTC 
ACT ATA GGC GGT TGT GTG TCA CTG TGG TTT TAG AGC TAG AAA 
TAGC-3′; ΔPIDD(97) sequence: 5′-TTA ATA CGA CTC ACT ATA 
GGC TTG GAC CTG TAC CCC GGG TTT TAG AGC TAG AAA TAGC-3′;  
ΔRAI DD(57) sequence: 5′-TTA ATA CGA CTC ACT ATA GGC CCA GGG 
AAA CTC CTG TAG TTT TAG AGC TAG AAA TAGC-3′; ΔRAI DD(76) 
sequence: 5′-TTA ATA CGA CTC ACT ATA GGA GGA GCA TTG TTT 
TCC GGG TTT TAG AGC TAG AAA TAGC-3′; and universal reverse 
primer: 5′-AGC ACC GAC TCG GTG CCA CT-3′. sgRNAs were gener-
ated by in vitro transcription using the Hiscribe T7 high-yield RNA 
synthesis kit (New England Biolabs, Inc.). Purified sgRNA (0.5 µg) 
was incubated with Cas9 protein (1 µg, PNA Bio) for 10 min at room 
temperature. HeLa.C2 Pro-BiFC cells were electroporated with the 
sgRNA/Cas9 complex using the Neon transfection system (Thermo 
Fisher Scientific) at 1,005 V, 35 ms, and two pulses.
Transient transfection and siRNA assays
105 HeLa cells were transfected with appropriate plasmids using 
Lipofectamine 2000 transfection reagent (Invitrogen) according to 
manufacturer’s instructions. Cells were transfected with amounts of 
the relevant expression plasmids as described in the figure legends. 
SiRNA transfections were performed using Hiperfect (QIA GEN) or 
Dharmafect (GE Healthcare) according to the manufacturer’s instruc-
tions. Cells were exposed to drugs at 48  h posttransfection. Control 
siRNAs were siLACZ or siCyclophilin B.  NPM1 siRNAs were HP- 
validated siRNAs from QIA GEN (NPM1-1 sequence, 5′-AAG AAT 
TGC TTC CGG ATG ACT-3′; NPM1-8 sequence 5′-AAT GTC TGT ACA 
GCC AAC GGT-3′). Stable shRNA-expressing HeLa cell lines were de-
scribed previously (Ando et al., 2012). PIDD siRNAs were ON-TAR 
GETplus PIDD1 SMA RTpool (target sequences: 5′-GAG CAG AUC 
CGU CAC AUGC-3′; 5′-GGA CGU GGC UGA AGA GGUG-3′; 5′-CCA 
GAA AUG CCC AGA CUGU-3′; and 5′-CCU CAG AUU UGG ACA 
GCUU-3′; GE Healthcare).
Microscopy
Cells were imaged using a spinning disk confocal microscope (ZEI SS) 
equipped with a CSU-X1A 5000 spinning disk unit (Yokogawa Electric 
Corp.), multilaser module with wavelengths of 458, 488, 514, and 561 
nm, and an Axio Observer Z1 motorized inverted microscope equipped 
with a precision motorized XY stage (ZEI SS). Images were acquired 
with a Zeiss Plan-Neofluar 40× 1.3-NA or 64× 1.4-NA objective on an 
Orca R2 CCD camera using Zen 2012 software (ZEI SS). Cells were 
plated on dishes containing coverslips coated with fibronectin (MatTek 
Corporation) 24 h before treatment or transfection.
Image analysis
At least 30 individual images were acquired for each treatment. Cells 
expressing the BiFC components were identified by fluorescence of the 
linked mCherry protein in stable cell lines or fluorescence of a trans-
fection reporter in transient transfection experiments. Images were an-
alyzed using Zen 2012 by counting the total number of cells per image 
and those with fluorescence in the cytosol, nucleus, or nucleolus. For 
3D imaging, Venus and Cerulean channel image data were analyzed 
to determine the relative localization of caspase-2 BiFC and nuclear 
(Histone H2A), cytoskeletal (actin), or nucleolar proteins (NPM1, 
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nucleolin, and fibrillarin), respectively. To analyze z-stacks, a line 
profile was drawn along the x-direction at the same y-position in each 
image. For each image, the yellow and cyan intensities along the line 
profile were linearly normalized to have a minimum of 0 and maximum 
of 1. Surface plots of normalized intensity in the x–z plane were gener-
ated in Matlab using the surfl function and custom color maps.
Immunofluorescence
Cells were washed in 3× 2 ml PBS and fixed in 3% (wt/vol) PFA in 
PBS, pH 7.2, for 10 min. Cells were washed for 3× 5 min in PBS fol-
lowed by permeabilization in PBS and 0.15% (vol/vol) Triton S-100 for 
10 min. Cells were blocked in FX image enhancer (Invitrogen) for 30 
min and then stained with the anti-NPM1 antibody at a 1:100 dilution 
in PBS and 2% (wt/vol) BSA for 1 h. After washing in PBS and 2% 
(wt/vol) BSA, the cells were incubated with anti-mouse Alexa Fluor 
488–conjugated secondary antibody (Invitrogen) at a 1:500 dilution 
in 2% (wt/vol) BSA for 45 min. Cells were washed in PBS and im-
aged as described earlier.
Flow cytometry and TUN EL staining
Venus- and mCherry-positive cells were quantified by flow cytometry 
and analyzed with FloJo software. TUN EL assays were performed 
using the APO-BRDU kit (BD) according to the manufacturer’s recom-
mendation. In brief, the cells were fixed with 1% PFA (Sigma-Aldrich) 
in PBS for 1 h on ice, washed in PBS, and incubated with 70% ethanol 
at −20°C overnight. The cells were then washed and incubated with 
DNA labeling solution containing TdT and BrdU for 4 h at 37°C. The 
cells were washed and incubated in the staining buffer containing 
FITC-labeled anti-BrdU antibody for 30 min at RT, and a mixture of 
PI/RNase was added. After 30-min incubation at RT, the cells were 
analyzed by flow cytometry. The threshold for TUN EL positivity was 
determined as the maximal TUN EL signal observed in nontreated 
cells. For annexin V binding, cells were resuspended in 200 µl annexin 
V binding buffer (10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, and 1.8 mM CaCl2) supplemented with 2 µl annexin V-FITC 
(Invitrogen). Annexin V–positive cells were quantitated by flow cytom-
etry. AlamarBlue-based cell viability assays were performed as previ-
ously described (Thompson et al., 2015).
Nucleolar isolation
Nucleoli were isolated after a protocol adapted from Mitrea et al. 
(2016). 4 × 107 HeLa cells were treated overnight as indicated in the 
figure legends and collected by trypsinization. Cells were washed in 
10 ml PBS and centrifuged at 400 g for 5 min. Cell pellets were re-
suspended in five pellet volumes of nucleolar isolation buffer (NIB; 
10 mM Tris, 2 mM MgCl2, and 0.5 mM EDTA) with complete protease 
inhibitor (Roche) and incubated at RT for 2 min and then on ice for 10 
min. Plasma membranes were disrupted by the addition of 10% (vol/
vol) IGE PAL to a final concentration of 1% and mixed by gentle pipet-
ting. Nuclei were isolated by centrifugation at 500 g for 3 min. The su-
pernatant was removed and stored as the cytoplasmic fraction, and the 
pellets were washed in 10–15 pellet volumes of NIB and 1% IGE PAL. 
Nuclear pellets were then resuspended in 10 pellet volumes of NIB and 
sonicated on ice at 20% power for 12 cycles of 1 s on followed by 5 s 
off on an XL 2020 sonicator fitted with a microtip probe (Misonix). The 
samples were centrifuged, and the supernatant was stored as the nucle-
oplasmic fraction. The pellet was washed once more with 10–15 pellet 
volumes of NIB and finally resuspended in 50–100 µl NIB.
Immunoblotting and coimmunoprecipitation
Cell lysates were resolved by SDS-PAGE. The proteins were trans-
ferred to nitrocellulose (Bio-Rad Laboratories) and immunodetected 
using appropriate primary and peroxidase-coupled secondary antibod-
ies (GE Healthcare). Proteins were visualized by West Pico and West 
Dura chemiluminescence Substrate (Thermo Fisher Scientific). Lysates 
for immunoprecipitation were prepared in 1% or 0.1% NP-40 buffer 
(1% or 0.1% NP-40, 50 mM Tris-HCl, pH 8.0, 150–250 mM NaCl, 
5  mM EDTA, 1  mM PMSF, protease inhibitors cocktail [Complete 
Mini; Roche], and phosphatase inhibitor cocktail [PhosSTOP; Roche]). 
For endogenous IPs, whole-cell lysates or nuclear extracts (10–20 mg) 
were mixed with Protein-G magnetic beads (Invitrogen; 30 µl of a 50% 
slurry) and anti-NPM1 (FC-61991), C-terminal anti-PIDD (Anto1 
or AL233), or N-terminal anti-PIDD (S-17) antibody (3–5 µg, 1  ml 
final volume) overnight at 4°C on a rotating wheel. Beads were then 
washed three times with PBS, resolved by SDS-PAGE, and probed with 
anti-PIDD (H-300 [1:200 dilution]), anti-PIDD (Anto-1), anti-NPM1 
(#3542), or anti-PIDD (S-17) detected with the corresponding second-
ary antibodies or mouse TrueBlot HRP-conjugated secondary antibod-
ies [eBioscience]). For anti-Flag IPs, whole-cell lysates (0.15–6.00 mg) 
were mixed with 20 µl beads (50% slurry) and mouse anti-Flag M2 
antibody (3 µg) in 0.1% NP-40 buffer (500 µl final volume) overnight 
at 4°C on a rotating shaker. Beads were then washed three times with 
PBS, resolved by SDS-PAGE, and analyzed by Western blot.
mRNA injections and acridine orange labeling in zebrafish embryos
Previously validated antisense morpholino oligonucleotides (MOs) 
targeted to npm1a and npm1b (5′-TAA TGT TAT CCT CCA TTT TTG 
CGCG-3′ and 5′-GAC CCA TCT GTT CGA GAT CCA TGTC-3′, respec-
tively; Bolli et al., 2010) were synthesized by Gene Tools, LLC, and 
injected into one-cell-stage embryos as previously described (Sidi et 
al., 2008; Bolli et al., 2010). 24 h embryos were stained with acridine 
orange (10 µg/ml final) as previously described (Sidi et al., 2008) and 
imaged with an SMZ 1500 fluorescence microscope (Nikon).
Statistical analysis
Statistical comparisons were performed using two-tailed Student’s t 
test calculated using Prism 6.0 (GraphPad Software).
Online supplemental material
Fig. S1 shows that caspase-2 BiFC localizes to the nucleus in response 
to several DNA damage inducers. Fig. S2 shows detailed imaging 
analysis of localization of the nucleolar caspase-2 complex in relation 
to nucleolar proteins. Fig. S3 accompanies Fig. 5 and shows the full 
analysis of the PIDD and RAI DD knockout and knockdown cells. Fig. 
S4 shows that NPM1 binds to PIDD and demonstrates specificity of 
the PIDD s17 antibody. Fig. S5 shows the localization of NPM1 in 
response to DNA damage and that NPM1 is required for caspase-2 
cleavage and apoptosis in response to DNA-damaging agents. Video 1 
shows the localization of camptothecin-induced caspase-2 BiFC in the 
nucleolus. Table S1 lists the NPM1 peptide sequences pulled down 
with Flag-PIDD immunoprecipitation.
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